Merck Collaborates with Amathus Therapeutics to Develop Treatments for Neurodegenerative Diseases

 Merck Collaborates with Amathus Therapeutics to Develop Treatments for Neurodegenerative Diseases

Merck Collaborates with Amathus Therapeutics to Develop Treatments for Neurodegenerative Diseases

Shots:

  • Amathus to receive upfront and will be eligible for ~$500M milestones/program, if Merck exercise its option and will be responsible for identifying & progressing novel chaperone activators through preclinical discovery
  • Merck to get an option to acquire Amathus Therapeutics along with its pipeline of mitochondrial targeted candidate to treat neurodegenerative disorders and renal diseases
  • Following the exercise of the option, Merck will lead the clinical development and commercialization of therapies for neurodegenerative diseases

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Linkedin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post